Please provide your email address to receive an email when new articles are posted on . Percentages of patients who experienced breakthrough reactions decreased from 70% to 52% and then 43%.
A digital intervention to enhance engagement with oral oncolytic treatments and assess patient experiences with novel therapies. Severity distribution of initial HSRs and BTRs.